Evaluating The Clinicopathologic Characteristics and Survival Outcome of Breast Cancer Patients with Isolated Brain Metastases after Adjuvant Treatment or at Initial Diagnosis

Basit Öğe Kaydı
dc.contributor.authorBoruban, Cem
dc.contributor.authorGulyer, Huseyin
dc.contributor.authorAltundag, Kadri
dc.contributor.authorArtac, Mehmet
dc.contributor.authorGuler, Tunc
dc.contributor.authorCengiz, Mustafa
dc.date.accessioned2024-02-23T14:34:25Z
dc.date.available2024-02-23T14:34:25Z
dc.date.issued2012
dc.departmentNEÜen_US
dc.description.abstractCNS metastases usually appears late in the progression of metastatic breast cancer. Classical approach is evaluating and treating them when symptoms become evident. We evaluated the survival and described clinicopathologic characteristics of patients in whom the brain metastases after adjuvant treatment or at initial diagnosis are the first and the only side. Authors retrospectively evaluated about 3600 patients with breast cancer treated in two university hospitals. In those 31 patients with first and only metastases to brain and no other metastases were evaluated. ER, PR, cerbB2 status T, N stage, grade, adjuvant taxane, trastuzumab, hormonal treatment, trastuzumab and platine use after brain metastases didn't effect the survival. Surgery and WBRT may be more effective in cerbB2 negative patients, WBRT in cerbB2 positive ones. (p=0.06). The survival outcome may be better in pre and perimenouposal women. The mOS of pre and perimenopausal, postmenopausal women were 17.7 months and 10.3 months respectively (p=0.06) and lapatinib may affect the mOS of patients with isolated brain metastases. Some prognostic factor may help us to foresee which group may benefit more from which treatment modality. The need for studies with larger groups of patients is obvious.en_US
dc.identifier.doi10.29333/ejgm/82442
dc.identifier.endpage269en_US
dc.identifier.issn1304-3889
dc.identifier.issn1304-3897
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-84874220024en_US
dc.identifier.startpage265en_US
dc.identifier.urihttps://doi.org/10.29333/ejgm/82442
dc.identifier.urihttps://hdl.handle.net/20.500.12452/15607
dc.identifier.volume9en_US
dc.identifier.wosWOS:000421895800009en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherModestum Ltden_US
dc.relation.ispartofEuropean Journal Of General Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBreast Canceren_US
dc.subjectIsolated Brain Metastasesen_US
dc.subjectTreatmenten_US
dc.subjectLapatiniben_US
dc.titleEvaluating The Clinicopathologic Characteristics and Survival Outcome of Breast Cancer Patients with Isolated Brain Metastases after Adjuvant Treatment or at Initial Diagnosisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu